Focusing on earlier diagnosis of Alzheimer's disease

References

• World Health Organization. Dementia (2022). Available at: https://www.who.int/news-room/fact-sheets/detail/dementia ( Accessed: 24 April 2023).
   Google Scholar
• Cohen S, Cummings J, Knox S, Potashman M, Harrison J. Clinical trial endpoints and their clinical meaningfulness in early stages of Alzheimer's disease. J. Prev. Alzheimers. Dis. 9(3), 507–522 (2022).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Lopez O, Armstrong MJ et al. Practice guideline update summary: mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90(3), 126–135 (2018).
   PubMed Web of Science ®Google Scholar
• Petersen RC. Mild cognitive impairment. Continuum (Minneap Minn) 22(2 Dementia), 404–418 (2016).
   PubMedGoogle Scholar
• Gustavsson A, Norton N, Fast T et al. Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimers Dement. 19(2), 658–670 (2023).
   PubMed Web of Science ®Google Scholar
• Amjad H, Roth DL, Sheehan OC, Lyketsos CG, Wolff JL, Samus QM. Underdiagnosis of dementia: an observational study of patterns in diagnosis and awareness in US older adults. J. Gen. Intern. Med. 33(7), 1131–1138 (2018).
   PubMed Web of Science ®Google Scholar
• Alzheimer's Disease International, McGill University. World Alzheimer Report 2021: journey through the diagnosis of dementia (2021). Available at: https://www.alzint.org/resource/world-alzheimer-report-2021/ ( Accessed: 24 April 2023).
   Google Scholar
• United States Food and Drug Administration. Draft guidance document. Alzheimer's disease: developing drugs for treatment guidance for industy (2018). Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/alzheimers-disease-developing-drugs-treatment-guidance-industy ( Accessed: 24 April 2023).
   Google Scholar
• Assuncao SS, Sperling RA, Ritchie C et al. Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease. Alzheimers Res. Ther. 14(1), 54 (2022).
   PubMed Web of Science ®Google Scholar
• Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of early Alzheimer's disease: clinical practice in 2021. J. Prev. Alzheimers. Dis. 8(3), 371–386 (2021).
   PubMed Web of Science ®Google Scholar
• Budd Haeberlein S, Aisen PS, Barkhof F et al. Two randomized Phase III studies of aducanumab in early Alzheimer's disease. J. Prev. Alzheimers Dis. 9(2), 197–210 (2022).
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration. Prescribing information for ADUHELM (aducanumab-avwa) injection, for intravenous use (2021). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s000lbl.pdf ( Accessed: 24 April 2023).
   Google Scholar
• United States Food and Drug Administration. Prescribing information for LEQEMBI (lecanemab-irmb) injection, for intravenous use (2023). Available at: https://www.leqembi.com/-/media/Files/Leqembi/Prescribing-Information.pdf?hash=3d7bf1a2-5db2-4990-8388-81086f415676 ( Accessed: 24 April 2023).
   Google Scholar
• van Dyck CH, Swanson CJ, Aisen P et al. Lecanemab in early Alzheimer's disease. N. Engl. J. Med. 388(1), 9–21 (2023).
   PubMed Web of Science ®Google Scholar
• Csukly G, Sirály E, Fodor Z et al. The differentiation of amnestic type MCI from the non-amnestic types by structural MRI. Front. Aging Neurosci. 8, 52 (2016).
   PubMed Web of Science ®Google Scholar
• Tifratene K, Robert P, Metelkina A, Pradier C, Dartigues JF. Progression of mild cognitive impairment to dementia due to AD in clinical settings. Neurology 85(4), 331–338 (2015).
   PubMed Web of Science ®Google Scholar
• Rojas JC, Bettcher BM. Chapter 16. Non-amnestic mild cognitive impairment. In: The Behavioral Neurology of Dementia. Miller BM, Boeve BF. ( Eds)., Cambridge University Press, Cambridge, UK, 232–244 (2016).
   Google Scholar
• Alzheimer's Association. 2022 Alzheimer's disease facts and figures. Alzheimer's Dementia 18(4), 700–789 (2022).
   PubMed Web of Science ®Google Scholar
• McGirr A, Nathan S, Ghahremani M, Gill S, Smith EE, Ismail Z. Progression to dementia or reversion to normal cognition in mild cognitive impairment as a function of late-onset neuropsychiatric symptoms. Neurology 98(21), e2132–e2139 (2022).
   PubMed Web of Science ®Google Scholar
• Davis M, Connell TO, Johnson S et al. Estimating Alzheimer's disease progression rates from normal cognition through mild cognitive impairment and stages of dementia. Curr. Alzheimer Res. 15(8), 777–788 (2018).
   PubMed Web of Science ®Google Scholar
• Boada M, Lanctot K, Tariot P et al. Time to progression through AD disease stages & associated probability of institutionalization. Presented at: 9th Congress of the European Academy of Neurology. Budapest, Hungary, 1–4 July 2023.
   Google Scholar
• Evans S, McRae-McKee K, Hadjichrysanthou C et al.; Australian Imaging Biomarkers and Lifestyle flagship study of ageing; Predictors of Cognitive Decline Among Normal Individuals (BIOCARD) study; Add Neuro Med Consortium. Alzheimer's disease progression and risk factors: a standardized comparison between six large data sets. Alzheimers Dement. (NY) 5, 515–523 (2019).
   PubMedGoogle Scholar
• Butler LM, Houghton R, Abraham A, Vassilaki M, Durán-Pacheco G. Comorbidity trajectories associated with Alzheimer's disease: a matched case-control study in a United States claims database. Front. Neurosci. 15, 749305 (2021).
   PubMed Web of Science ®Google Scholar
• Cummings J, Hahn-Pedersen JH, Eichinger C, Freeman C, Clark A, Lanctôt K. Exploring the relationship between comorbidities and Alzheimer's disease progression assessed using the Clinical Dementia Rating scale: a systematic literature review. Presented at: ISPOR Europe 2022. Vienna, Austria, 6–9 November 2022.
   Google Scholar
• Lanctôt K, Hahn-Pedersen JH, Eichinger C et al. Burden of illness in people with Alzheimer's disease: a systematic review of epidemiology, comorbidities and mortality. J. Prev. Alzheimers Dis. 1, 1–11 (2023).
   Google Scholar
• Qui W, Clark A, Thim Hansen C, Michalak W, Raket LL, Kornholt J. BMI and prevalence of comorbidities in patients with clinical Alzheimer's disease: results from two large real-world databases. Presented at: Alzheimer's Association International Conference (AAIC 2022). San Diego, CA, USA, 31 July–4 August 2022.
   Google Scholar
• Zhang X, Tong T, Chang A et al. Midlife lipid and glucose levels are associated with Alzheimer's disease. Alzheimers Dement. 19(1), 181–193 (2023).
   PubMed Web of Science ®Google Scholar
• Marquié M, García-Gutiérrez F, Orellana A et al. The synergic effect of AT(N) profiles and depression on the risk of conversion to dementia in patients with mild cognitive impairment. Int. J. Mol. Sci. 24(2), 1371 (2023).
   PubMed Web of Science ®Google Scholar
• Wang KN, Page AT, Etherton-Beer CD. Mild cognitive impairment: to diagnose or not to diagnose. Australas J. Ageing 40(2), 111–115 (2021).
   PubMed Web of Science ®Google Scholar
• Xanthopoulou P, McCabe R. Subjective experiences of cognitive decline and receiving a diagnosis of dementia: qualitative interviews with people recently diagnosed in memory clinics in the UK. BMJ Open 9(8), e026071 (2019).
   PubMed Web of Science ®Google Scholar
• Dubois B, Padovani A, Scheltens P, Rossi A, Dell'Agnello G. Timely diagnosis for Alzheimer's disease: a literature review on benefits and challenges. J. Alzheimers Dis. 49(3), 617–631 (2016).
   PubMed Web of Science ®Google Scholar
• Rasmussen J, Langerman H. Alzheimer's disease – why we need early diagnosis. Degener. Neurol. Neuromuscul. Dis. 9, 123–130 (2019).
   PubMed Web of Science ®Google Scholar
• Bayly M, Elliot V, Kosteniuk J, Froehlich Chow A, Peacock S, O'Connell ME. Does early-stage intervention improve caregiver well-being or their ability to provide care to persons with mild dementia or mild cognitive impairment? A systematic review and meta-analysis. Psychol. Aging 36(7), 834–854 (2021).
   PubMed Web of Science ®Google Scholar
• Nakanishi M, Igarashi A, Ueda K et al. Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study. Curr. Med. Res. Opin. 37(8), 1331–1339 (2021).
   PubMed Web of Science ®Google Scholar
• Robinson RL, Rentz DM, Andrews JS et al. Costs of early stage Alzheimer's disease in the United States: cross-sectional analysis of a prospective cohort study (GERAS-US)1. J. Alzheimers Dis. 75(2), 437–450 (2020).
   PubMed Web of Science ®Google Scholar
• Petersen RC, Aisen PS, Andrews JS et al. Expectations and clinical meaningfulness of randomized controlled trials. Alzheimers Dement. 2023, 1–7 (2023).
   Google Scholar
• Razavi M, Herring W, Gillis C, Maserejian N, Pemberton-Ross P, Nejati M. Economic burden of daily transitions to later stages of AD dementia in the US. Presented at: 15th Clinical Trials on Alzheimer's Disease (CTAD). San Francisco, CA, USA, 22 December 2022.
   Google Scholar
• Cummings J, Ritter A, Zhong K. Clinical trials for disease-modifying therapies in Alzheimer's disease: a primer, lessons learned, and a blueprint for the future. J. Alzheimers Dis. 64(s1), S3–S22 (2018).
   PubMedGoogle Scholar
• Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer's disease drug development pipeline: 2023. Alzheimers Dement. (NY) 9(2), e12385 (2023).
   PubMedGoogle Scholar
• Golde TE. Disease-modifying therapies for Alzheimer's disease: more questions than answers. Neurotherapeutics 19(1), 209–227 (2022).
   PubMed Web of Science ®Google Scholar
• Alzheimer's Clinical Trials Consortium, Biogen, National Institute on Aging (NIA). AHEAD 3–45 study: a study to evaluate efficacy and safety of treatment with lecanemab in participants with preclinical Alzheimer's disease and elevated amyloid and also in participants with early preclinical Alzheimer's disease and intermediate amyloid (2020). Available at: https://clinicaltrials.gov/ct2/show/NCT04468659 ( Accessed 6 March 2023).
   Google Scholar
• Sims JR, Zimmer JA, Evans CD et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6), 512–527 (2023).
   PubMed Web of Science ®Google Scholar
• Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France. Rev. Neurol. (Paris) 178(10), 999–1010 (2022).
   PubMed Web of Science ®Google Scholar
• Dubois B, Villain N, Frisoni GB et al. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol. 20(6), 484–496 (2021).
   PubMed Web of Science ®Google Scholar
• Jack CR Jr, Bennett DA, Blennow K et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 14(4), 535–562 (2018).
   PubMed Web of Science ®Google Scholar
• Frisoni GB, Altomare D, Thal DR et al. The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat. Rev. Neurosci. 23(1), 53–66 (2022).
   PubMed Web of Science ®Google Scholar
• van der Flier WM, Scheltens P. The ATN framework-moving preclinical Alzheimer disease to clinical relevance. JAMA Neurol. 79(10), 968–970 (2022).
   PubMed Web of Science ®Google Scholar
• Tran J, Nimojan T, Saripella A et al. Rapid cognitive assessment tools for screening of mild cognitive impairment in the preoperative setting: a systematic review and meta-analysis. J. Clin. Anesth. 78, 110682 (2022).
   PubMed Web of Science ®Google Scholar
• Alegret M, Muñoz N, Roberto N et al. A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory(R)) for the early detection of Alzheimer's disease. Alzheimers Res. Ther. 12(1), 25 (2020).
   PubMed Web of Science ®Google Scholar
• Alegret M, García-Gutiérrez F, Muñoz N et al. FACEmemory®, an innovative online platform for episodic memory pre-screening: findings from the first 3,000 participants. J. Alzheimers Dis. 97(3), 1173–1187 (2024).
   PubMedGoogle Scholar
• Bruun M, Frederiksen KS, Rhodius-Meester HFM et al. Impact of a clinical decision support tool on dementia diagnostics in memory clinics: the PredictND validation study. Curr. Alzheimer. Res. 16(2), 91–101 (2019).
   PubMed Web of Science ®Google Scholar
• Meier IB, Buegler M, Harms R, Seixas A, Çöltekin A, Tarnanas I. Using a Digital Neuro Signature to measure longitudinal individual-level change in Alzheimer's disease: the Altoida large cohort study. NPJ Digit. Med. 4(1), 101 (2021).
   PubMed Web of Science ®Google Scholar
• Bernstein JPK, Dorociak KE, Mattek N et al. Passively-measured routine home computer activity and application use can detect mild cognitive impairment and correlate with important cognitive functions in older adulthood. J. Alzheimers Dis. 81(3), 1053–1064 (2021).
   PubMed Web of Science ®Google Scholar
• Rawtaer I, Mahendran R, Kua EH et al. Early detection of mild cognitive impairment with in-home sensors to monitor behavior patterns in community-dwelling senior citizens in Singapore: cross-sectional feasibility study. J. Med. Internet Res. 22(5), e16854 (2020).
   PubMed Web of Science ®Google Scholar
• Sabbagh MN, Boada M, Borson S et al. Early detection of mild cognitive impairment (MCI) in primary care. J. Prev. Alzheimers Dis. 7(3), 165–170 (2020).
   PubMed Web of Science ®Google Scholar
• White L, Ingraham B, Larson E, Fishman P, Park S, Coe NB. Observational study of patient characteristics associated with a timely diagnosis of dementia and mild cognitive impairment without dementia. J. Gen. Intern. Med. 37(12), 2957–2965 (2022).
   PubMed Web of Science ®Google Scholar
• Angioni D, Delrieu J, Hansson O et al. Blood biomarkers from research use to clinical practice: what must be done? A report from the EU/US CTAD Task Force. J. Prev. Alzheimers Dis. 9(4), 569–579 (2022).
   PubMed Web of Science ®Google Scholar
• van Maurik IS, Broulikova HM, Mank A et al. A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting. Alzheimers Dement. 19(5), 2006–2013 (2023).
   PubMed Web of Science ®Google Scholar
• Hansson O, Edelmayer RM, Boxer AL et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 18(12), 2669–2686 (2022).
   PubMed Web of Science ®Google Scholar
• Pichet Binette A, Janelidze S, Cullen N et al. Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 19(4), 1403–1414 (2022).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ortiz F, Turton M, Kac PR et al. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration. Brain 146(3), 1152–1165 (2023).
   PubMed Web of Science ®Google Scholar
• Ashton N, Janelidze S, Al Khleifat A et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12(1), 3400 (2021).
   PubMed Web of Science ®Google Scholar
• Simrén J, Andreasson U, Gobom J et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years. Brain Commun. 4(4), fcac174 (2022).
   PubMedGoogle Scholar
• Perneczky R, Jessen F, Grimmer T et al. Anti-amyloid antibody therapies in Alzheimer's disease. Brain 146(3), 842–849 (2023).
   PubMed Web of Science ®Google Scholar
• Galvin JE, Aisen P, Langbaum JB et al. Early stages of Alzheimer's disease: evolving the care team for optimal patient management. Front. Neurol. 11, 592302 (2020).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gomez O, Rodrigo A, Iradier F et al. The MOPEAD project: advancing patient engagement for the detection of “hidden” undiagnosed cases of Alzheimer's disease in the community. Alzheimers Dement. 15(6), 828–839 (2019).
   PubMed Web of Science ®Google Scholar
• Boada M, Rodrigo A, Jessen F et al. MOPEAD consortium Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: results from the MOPEAD project. Alzheimers Dement. 18(6), 1119–1127 (2022).
   PubMed Web of Science ®Google Scholar
• Hampel H, Vergallo A, Iwatsubo T et al. Evaluation of major national dementia policies and health-care system preparedness for early medical action and implementation. Alzheimers Dement. 18(10), 1993–2002 (2022).
   PubMed Web of Science ®Google Scholar
• Ball DE, Mattke S, Frank L et al. A framework for addressing Alzheimer's disease: without a frame, the work has no aim. Alzheimers Dement. 19(4), 1568–1578 (2022).
   PubMed Web of Science ®Google Scholar
• Blasco D, Roberts JS. Implications of emerging uses of genetic testing for Alzheimer's Disease. J. Prev. Alzheimers Dis. 3(10), 359–361 (2023).
   Google Scholar
• Cummings J, Apostolova L, Rabinovici GD et al. Lecanemab: appropriate use recommendations. J. Prev. Alzheimers Dis. 3(10), 362–377 (2023).
   Google Scholar
• Fabrizio C, Termine A, Caltagirone C et al. Artificial intelligence for Alzheimer's disease: promise or challenge? Diagnostics (Basel) 11(8), 1473 (2023).
   Google Scholar
• University College London. Portico Magazine. The beginning of the end? (Autumn 2023). Available at: https://magazine.ucl.ac.uk/disease-modifying-dementia-therapies/ ( Accessed: 08 January 2024).
   Google Scholar